COVID-19 Guidance About Chloroquine
The Food and Drug Administration (FDA) has announced the removal of Emergency Use Authorizations (EUA) for chloroquine (CQ) and hydroxychloroquine (HCQ) to treat COVID-19. The announcement follows the FDA’s determination that CQ and HCQ are unlikely effective treatments for COVID-19. In addition, the FDA further indicated the potential benefit does not outweigh the potential serious cardiovascular events and other adverse effects that can be caused by CQ and HCQ.2
Based on this information, the Arkansas Department of Health has updated its guidance related to hydroxychloroquine and chloroquine. The utilization of CQ and HCQ for treatment of COVID-19 should be avoided in both outpatient and hospitalized settings. HCQ that has been distributed through the Strategic National Stockpile is no longer authorized under the EUA to treat hospitalized patients for COVID-19, unless they had already started treatments.
Chloroquine and hydroxychloroquine should be administered, prescribed and dispensed for FDA approved medical conditions under supervision of a patient’s healthcare provider.
Healthcare professionals currently in the middle of treating patients with chloroquine or hydroxychloroquine as part of the EUA should refer to the Frequently Asked Question document developed by the FDA, which can be located at the provided link: https://www.fda.gov/media/138946/download.
Please note, information provided is constantly updated and could be subject to change.
- Chloroquine Warning
- Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Hydroxychloroquine Sulfate and Chloroquine Phosphate (6/15/2020)
- Letter of Revocation from FDA